On Monday, Shares of Exelixis, Inc. (NASDAQ:EXEL), inclined 2.03% to $3.51, during its last trading session.
Exelixis Inc., declared positive results from a two-stage phase 2 investigator-sponsored trial (IST) evaluating cabozantinib in patients with advanced RET-rearranged lung cancers. Data were stated for the first stage, which enrolled 16 patients. The objective response rate (ORR) was 38% (6/16), with a median duration of response of 8 months. Although the trial is still accruing, it has already met its primary endpoint, surpassing the predefined targeted number of five objective responses. Alexander Drilon, M.D. of New York’s Memorial Sloan Kettering Cancer Center (MSKCC) will present the data (Abstract #8007) recently during an oral abstract session at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.
“Constitutive activation of receptor tyrosine kinases by mutation or rearrangement is an oncogenic event in a substantial proportion of patients with non-small cell lung cancer (NSCLC), and comprises the activation of RET by gene rearrangement in about 1-2% of patients with adenocarcinoma histology,” said Dr. Drilon, the study’s principal investigator. “Cabozantinib is an active therapy in RET-rearranged lung cancers, as demonstrated by the durable objective responses observed in the first stage of this study. While this trial continues to accrue patients to complete its second stage, it has already met its primary endpoint. Further investigation is clearly warranted.”
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
At the end of Monday’s trade, Shares of Perfect World Co., Ltd. (ADR) (NASDAQ:PWRD), lost -1.51% to $19.52.
Perfect World Co., declared the latest developments in the Zhi-Xing China-Perfect World US-China Young Leaders Fellowship Program (“Zhi-Xing China Program”). This program aims to bring together young members of US and Chinese societies and was successfully launched at the end of December 2014 . On the evening of June 22 , local time, Chinese Vice Premier Liu Yandong met with the first American representatives of the program for the first time, setting a new milestone.
The Zhi-Xing China program was launched by the China Education Association for International Exchange in partnership with the Eisenhower Foundation. The program is a pioneer initiative, embodying the co-operative spirit of the 5th US-China High-Level Consultation on People-to-People Exchange (CPE). It aims to build a platform for research and exchange between China and the United States , and targets U S-China bilateral relations and broaden channels for further cultural exchanges. Perfect World is honored to support and fund the Zhi-Xing China Program.
Perfect World Co., Ltd., through its auxiliaries, engages in the research, development, operation, and licensing of online games in the People’s Republic of China, the United States, Europe, Japan, Southeast Asia, and South Korea.
Finally, ResMed Inc. (NYSE:RMD), ended its last trade with 0.13% gain, and closed at $55.38.
ResMed Inc., declared that it will report its fourth quarter and fiscal year ended June 30, 2015 results on Thursday, July 30, 2015, after the New York Stock Exchange market close. A press release with ResMed’s results will be issued after 1:00 p.m. US Pacific Time and the company will host a webcast to talk about operating results and future outlook.
The earnings call is planned to start at 1:30 p.m. US Pacific Time and the live webcast of the call can be accessed on ResMed’s Investor Relations website at investors.resmed.com. Please go to this section of the website and click on the icon for the “Q4 2015 earnings webcast.”
ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and administration of respiratory disorders, with a focus on sleep-disordered breathing.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
